MOA: Management of Parkinsonism

Question 1

Levodopa

Answer 1

Anti-Parkinson Drug

Levodopa is a dopamine precursor that boosts DA synthesis - increases contents of DA vesicles and increases amounts of DA released

Question 2

Carbidopa

Answer 2

Anti-Parkinson Drug

Co-administered to inhibit PNS conversion of levodopa to dopamine, which allows therapeutic levels to reach the CNS at a lower dose

Question 3

Amantadine

Answer 3

Antiviral mixed with dopamine agonist that induces DA release.

Also, an antiviral that inhibits viral uncoating

Question 4

Apomorphine

Answer 4

Dopamine agonist mixed with amantadine to induce DA release

Question 5

Pramipexole

Answer 5

Dopamine agonist mixed with amantadine to induce DA release

Question 6

Ropinirole

Answer 6

Dopamine agonist mixed with amantadine to induce DA release

Question 7

Rotigotine

Answer 7

Dopamine agonist mixed with amantadine to induce DA release

Question 8

Entacapone

Answer 8

COMT Inhibitor

Inhibits catechol-O-methyltransferase, an enzyme that interferes with levodopa uptake

Question 9

Benztropine

Answer 9

Antimuscarinic Agents

Reduce cholinergic influence - block cholinergic receptors

Question 10

Biperiden

Answer 10

Antimuscarinic Agents

Reduce cholinergic influence - block cholinergic receptors

Question 11

Trihexphenidyl

Answer 11

Antimuscarinic Agents

Reduce cholinergic influence - block cholinergic receptors

Question 12

Resagiline

Answer 12

Monoamine oxidase inhibitor

Reduces DA metabolism - these MAOIs better inhibit metabolism/breakdown of dopamine & are nearly inactive against MAO in noradrenergic neurons

Question 13

Selegiline

Answer 13

Reduces DA metabolism - these MAOIs better inhibit metabolism/breakdown of dopamine & are nearly inactive against MAO in noradrenergic neurons